Riluzole–Rasagiline Hybrids: Toward the Development of Multi-Target-Directed Ligands for Amyotrophic Lateral Sclerosis
Claudia Albertini, Alessandra Salerno, Silvia Atzeni, Elisa Uliassi, Francesca Massenzio, Annalisa Maruca, Roberta Rocca, Marko Mecava, Filomena Silva, Débora Mena, Pedro Afonso Valente, Ana I. Duarte, Daniel Chavarria, Maicol Bissaro, Stefano Moro, Stephanie Federico, Giampiero Spalluto, Ondřej Soukup, Fernanda Borges, Stefano Alcaro, Barbara Monti, Paulo J. Oliveira, J. Carlos Menéndez, María Laura Bolognesi
Abstract
= 8.7 μM) might add a piece to the puzzle of its anti-ALS molecular profile.
Topics & Concepts
RiluzoleRasagilineExcitotoxicityAmyotrophic lateral sclerosisNeuroprotectionIn silicoPharmacologyEdaravoneChemistryOxidative stressNeuroscienceGlutamate receptorMedicineBiologyParkinson's diseaseBiochemistryReceptorInternal medicineGeneDiseaseAmyotrophic Lateral Sclerosis ResearchCholinesterase and Neurodegenerative DiseasesParkinson's Disease Mechanisms and Treatments